Premarket price
$220.46
+$5.02 · +2.33%
From Wednesday's $215.44 close
Revolution Medicines Rises 2.3% in Premarket After $39,800 RASONQUE Debut
Revolution Medicines has debuted its first commercial product in the U.S. following the launch of RASONQUE. The pancreatic cancer pill, taken once daily, is priced at $39,800 for a month’s supply.
Product launch · NASDAQ: RVMD
RASONQUE turns Revolution Medicines into a commercial oncology company
The approval risk has cleared. Prescription volume, payer access and net price now determine whether a $46.2 billion valuation can hold.
Market data: Aug. 27, 2026
04:30 EDT · premarket
04:30 EDT · premarket
Market value
$46.18B
214.34 million shares outstanding
30-day wholesale price
$39,800
$477,600 annualized sticker price
Launch signal
2,000+
Patients received early access before approval
Why investors care now
RBC expects $28 million of third-quarter sales and $148 million in the fourth. The Q4 forecast equals about 1,240 paid 30-day supplies per month at wholesale price, before discounts.
RVMD already trades near 42 times RBC's $1.1 billion 2027 sales estimate. The launch must convert clinical demand quickly to support that multiple.
Product card
| Item | Current fact |
|---|---|
| Brand / drug | RASONQUE / daraxonrasib |
| Dose | 300 mg oral tablet once daily |
| U.S. status | Approved and available |
| Label | Metastatic pancreatic adenocarcinoma after prior systemic therapy, or when multiagent therapy is unsuitable |
| Diagnostic | No companion test required |
| International | EMA phased review; not approved outside the U.S. |
RASolute 302: the clinical engine
| Measure | RASONQUE | Chemotherapy | Investor read |
|---|---|---|---|
| Median overall survival | 13.2 months | 6.7 months | 60% lower death risk; HR 0.40 |
| Progression-free survival | 7.2 months | 3.6 months | Roughly doubled; HR 0.49 |
| Objective response rate | 30% | 11% | 19-point advantage |
| Trial size | 500 adults, randomized 1:1 | FDA approved 6.5 months early | |
FDA figures published Aug. 26, 2026.
Valuation bridge
Market cap / 2027 sales42.0×$46.18B / $1.1B
Market cap / peak sales4.0×Using RBC's $11.5B global estimate
Wednesday volume2.05×3.51M vs 1.71M average
Balance sheet and spending
| June 30, 2026 | Amount | Signal |
|---|---|---|
| Cash and investments | $3.94B | Launch and pipeline runway |
| Q2 research spending | $394.9M | Up from $224.1M |
| Q2 general costs | $110.2M | Commercial buildout lifted costs |
| Q2 net loss | $644.4M | Includes $151M warrant revaluation |
| FY2026 operating-cost guide | $2.1B–$2.2B | Execution remains capital intensive |
Analyst frame
ConsensusBuy19 analysts
Strong Buy42%
Buy / Hold53% / 5%
Public.com consensus checked Aug. 27, 2026. RBC kept Outperform after approval.
Catalyst timeline
Apr. 13
Phase 3 survival data triggered a stock gain above 40%.
May
Expanded access began; more than 2,000 patients received treatment.
Aug. 26
FDA approval arrived 6.5 months before the target date.
Now
U.S. prescriptions begin at $39,800 per 30-day supply.
Next
First reported launch sales and net-price evidence.
What can move the stock
| Driver | Bull case | Pressure point |
|---|---|---|
| Access | Rapid payer coverage and early-access conversion | Prior authorization or reimbursement delays |
| Demand | Broad label without companion testing | Small eligible treated population or discontinuation |
| Net price | Limited discounting supports revenue per patient | Assistance and rebates widen gross-to-net gap |
| Safety | Oral regimen proves easier than chemotherapy | Skin toxicity, diarrhea, ILD or gastrointestinal events |
| Pipeline | Earlier-line and lung-cancer studies expand use | Trial setbacks leave valuation concentrated in one asset |
Source trail
All time-sensitive figures carry their source timestamp. Estimates are not guarantees.
Rasonque FDA Approval Lifts Revolution Medicines Stock 0.8% at $45.7 Billion Valuation
Rasonque won U.S. approval Wednesday, giving Revolution Medicines, Inc. its first commercial product. The stock rose 0.77% to $213.01 at 11:55 a.m. EDT.
Rasonque approval dashboard
Revolution Medicines moves from trial risk to launch risk
NASDAQ:RVMD · PRODUCT/COMMERCIAL CATALYST
Market data: August 26, 2026
11:55 EDT / 17:55 Europe/Warsaw
11:55 EDT / 17:55 Europe/Warsaw
RVMD price
$213.01
+$1.63 · +0.77%
Market value
$45.65B
≈ $351M added today
Session range
8.3%
$198.91 low · $216.50 high
Volume by 11:55
1.10M
64% of 1.71M daily average
Session price map
Range positions are scaled from the verified session low and high. This is not a minute-by-minute price chart.
What changed
Rasonque is now a first-in-class, once-daily oral RAS inhibitor for certain adults with metastatic pancreatic cancer.
First product revenueNow possible
PricingNot disclosed
AvailabilityNot disclosed
Expanded-access patients2,000+
Phase 3 survival comparison
Rasonque median overall survival13.2 months
Standard chemotherapy6.7 months
Absolute improvement+6.5 months
Relative improvement+97%
Trial population500 adults
Valuation versus operating base
| Metric | Amount | Ratio to market cap |
|---|---|---|
| Quoted market value | $45.65B | 100% |
| Cash and securities, June 30 | $3.94B | 8.6% |
| 2026 operating-expense midpoint | $2.15B | 4.7% |
| Q2 operating expenses | $505.1M | 1.1% |
| Q2 net loss | $644.4M | 1.4% |
Cash equals 1.83× the midpoint of the current annual expense guide. It is not a formal runway estimate.
Analyst expectations
Buy ratings18
Hold ratings1
Average target$222.89
Implied upside4.6%
Target range$179–$291
Based on Google Finance’s 19-analyst, three-month set at the market-data timestamp.
What the valuation requires
Launch pricing and reimbursementNear term
Initial prescriptions and net salesNext reports
First-line pancreatic expansionPhase 3
RAS-mutant lung cancer readoutExpected 2027
Broad peak-sales estimate>$20B
The >$20B estimate assumes success beyond today’s approved patient group; current market value is about 2.3× that figure.
Catalyst timeline
Phase 3 survival data established the approval case.
Company reported U.S. launch readiness and $3.94B liquidity.
FDA approved Rasonque for the initial metastatic setting.
Pricing, availability, reimbursement and prescription uptake.
Risk monitor
Commercial
Pricing remains unknown. Slow coverage decisions can defer revenue even after approval.
Execution
Manufacturing limits or weak real-world uptake would pressure launch estimates.
Valuation
The average analyst target offers only 4.6% upside. Failed expansion trials would narrow the revenue base.
Investor bridge
Approval creates the first direct sales channel for Revolution Medicines. The financial test is whether Rasonque’s launch and later-label expansion can grow into a $45.65 billion valuation while annual operating expenses run near $2.15 billion.
Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate
Tango Therapeutics shares rose in premarket trading Monday. The company posted positive early results for its pancreatic cancer drug combo and said it aims to advance the treatment into late-stage trials.
AT&T Faces $4.5 Billion Cash Flow Hurdle as Stock Eyes Next Move
AT&T Inc. shares dipped in premarket trading Monday, trailing the broader U.S. market. Investors are looking ahead to the telecom company’s next cash flow check and comments expected from CFO Pascal Desroches.
Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data
Revolution Medicines Inc shares gained in early U.S. premarket trading Monday after late-stage trial results reported its experimental pill for pancreatic cancer almost doubled survival against chemo. RVMD was last seen at $157.48, up $2.93, or 1.9%, ahead of the regular Nasdaq open. The company’s market cap hovered at about $31.2 billion. Nasdaq’s 2026 calendar does not list June 1 as a holiday—Memorial Day shows May 25 and Juneteenth June 19 as closures.
Revolution Medicines stock dives in premarket after report Merck walked away from takeover talks
Revolution Medicines, Inc. shares dropped roughly 22%, slipping to about $92 in premarket Monday, after news surfaced over the weekend that Merck ended acquisition discussions.
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus
Shares of Revolution Medicines slipped around 1.8% to $116.51 in early Monday trading, pulling back from a 52-week peak amid fresh analyst notes following a rollercoaster week of takeover rumors. The stock fluctuated between $113.47 and $119.58 during the session, pegging the company’s market cap at about $23 billion.
Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch
Merck & Co., Inc. shares closed down 0.4% on Friday at $110.53, and traders head into Monday with takeover chatter back in the tape. The Wall Street Journal reported Merck is in talks to buy Revolution Medicines in a deal valued around $28 billion to $32 billion.
Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week
Revolution Medicines wrapped up Friday with a 10.7% gain, closing at $118.64. The cancer-drug developer remains in focus amid ongoing takeover buzz heading into next week. Shares fluctuated between $109.88 and $125.79, with roughly 20.8 million shares changing hands.
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK
Merck & Co closed Friday 0.4% lower at $110.53 following reports that the pharmaceutical giant is negotiating to acquire cancer drug developer Revolution Medicines in a deal valued between $28 billion and $32 billion.
Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday
Revolution Medicines shares jumped 10.7% to close at $118.64 on Friday, hitting a session high of $125.79 amid merger rumors. The Financial Times reported that Merck is negotiating a potential $28 billion to $32 billion acquisition of the biotech.
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus
Merck & Co shares slipped on Friday following reports that the pharma giant is in talks to acquire cancer-focused biotech Revolution Medicines for as much as $32 billion. Merck ended the day down 0.4% at $110.53, after swinging between $110.26 and $112.46.
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod
Revolution Medicines shares jumped 10.7% to $118.64 in after-hours trading on Friday, after the Financial Times reported Merck was in advanced talks to buy the cancer-drug developer for $28 billion to $32 billion. The stock swung between $109.88 and $125.79 in the session on volume of about 20.6 million shares.
Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark
Shares of Revolution Medicines climbed on Friday as investors weighed a report that Merck is in talks to buy the cancer-drug developer for up to $32 billion. Revolution was up about 4.3% at $112.00, after touching $125.79 earlier in the session.
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play
Merck & Co Inc shares were up about 0.4% at $111.41 on Friday as investors weighed a report that the drugmaker is in talks to buy cancer biotech Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped nearly 16% in extended trading on Thursday after the Financial Times report, which said talks were not final and could still take weeks, with other large drugmakers still circling; Merck and Revolution did not respond to requests for comment. The potential acquisition would be the biggest in the sector since Pfizer’s $43 billion Seagen deal and would add Revolution’s late-stage RAS cancer drug candidate daraxonrasib; Mizuho analysts estimate Revolution’s RAS inhibitors could generate more than $10 billion in risk-adjusted sales by 2035 as Merck looks past Keytruda patent expiries later this decade.
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders
AbbVie Inc shares fell on Thursday after the drugmaker denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge that will dent its 2025 profit outlook. AbbVie stock was down 3.7% at $224.84 at 1:12 p.m. ET, after swinging between $231.93 and $223.84.
Revolution Medicines (RVMD) stock slips in premarket as AbbVie denies takeover talks, deal buzz lingers
Shares of Revolution Medicines fell 9.8% to $92.60 in premarket trading on Thursday, pulling back after a sharp, rumor-driven run-up in the prior session. Investing.com
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down
AbbVie Inc shares slipped 1.6% to about $229.64 in premarket trading on Thursday after the drugmaker denied it was in talks to buy cancer biotech Revolution Medicines and cut its 2025 profit view. Revolution’s stock fell 11.5% in extended trading after AbbVie’s statement, Reuters reported. Investing.com+1
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view
AbbVie shares were down about 1% at $231.11 in after-hours trading on Wednesday after the drugmaker denied a Wall Street Journal report that it was in advanced talks to buy cancer-drug developer Revolution Medicines, saying it “is not in discussions with Revolution Medicines.” The stock had closed up 4.2% at $233.42, while Revolution shares slid 11.5% late after jumping nearly 30% earlier, with the report pointing to a valuation around $20 billion. AbbVie has spent more than $20 billion on acquisitions since 2023 as its former blockbuster Humira lost patent protection. Reuters+1
AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg
AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines, the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Revolution shares jumped nearly 30% after the report, while AbbVie rose more than 5%. https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-talks-buy-biotech-revolution-medicines-wsj-reports-2026-01-07/
TechStock² Updates
